Sei Investments Co. Has $109,000 Holdings in OmniAb, Inc. (NASDAQ:OABI)

Sei Investments Co. raised its holdings in OmniAb, Inc. (NASDAQ:OABI) by 11.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 29,024 shares of the company’s stock after buying an additional 2,888 shares during the period. Sei Investments Co.’s holdings in OmniAb were worth $109,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently made changes to their positions in the business. Price T Rowe Associates Inc. MD lifted its stake in shares of OmniAb by 13.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 26,843 shares of the company’s stock valued at $146,000 after buying an additional 3,108 shares in the last quarter. Woodstock Corp raised its holdings in shares of OmniAb by 0.7% in the first quarter. Woodstock Corp now owns 748,428 shares of the company’s stock valued at $4,056,000 after purchasing an additional 5,426 shares during the last quarter. Simplicity Wealth LLC increased its holdings in OmniAb by 23.3% during the second quarter. Simplicity Wealth LLC now owns 42,160 shares of the company’s stock worth $158,000 after buying an additional 7,976 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its stake in shares of OmniAb by 66.0% in the first quarter. China Universal Asset Management Co. Ltd. now owns 22,321 shares of the company’s stock worth $121,000 after purchasing an additional 8,871 shares in the last quarter. Finally, Hartline Investment Corp purchased a new position in shares of OmniAb in the first quarter worth about $54,000. 72.08% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on OABI shares. Benchmark restated a “buy” rating and issued a $8.00 price objective on shares of OmniAb in a research report on Monday, August 19th. HC Wainwright reaffirmed a “buy” rating and set a $11.00 price objective on shares of OmniAb in a research note on Monday, August 12th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $7.00 price target on shares of OmniAb in a report on Friday, August 16th.

OmniAb Trading Up 3.1 %

Shares of NASDAQ:OABI opened at $4.04 on Friday. The stock’s 50-day moving average price is $4.21 and its 200-day moving average price is $4.43. OmniAb, Inc. has a 12-month low of $3.56 and a 12-month high of $6.72. The stock has a market capitalization of $475.16 million, a P/E ratio of -6.31 and a beta of -0.13.

OmniAb (NASDAQ:OABI) last posted its earnings results on Thursday, August 8th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.05. The company had revenue of $7.61 million for the quarter, compared to analysts’ expectations of $6.52 million. OmniAb had a negative return on equity of 20.21% and a negative net margin of 287.29%. During the same period last year, the firm earned ($0.15) earnings per share. As a group, research analysts predict that OmniAb, Inc. will post -0.58 EPS for the current year.

OmniAb Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.